Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-06-12 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of a business registration change related to the increase in registered capital due to the completion of stock incentive plan share registration. It mentions the change in registered capital and share capital, and the issuance of a new business license by the local market supervision bureau. The document is short (838 characters) and serves as a formal notice of the capital change and registration completion, not a detailed financial report or capital raising activity. This fits the definition of a Share Issue/Capital Change announcement (SHA).
2025-06-12 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the amounts, types, dates, and expected returns of financial products purchased with idle raised funds. It also describes the approval process, risk control measures, and impact on daily operations. The document is dated June 7, 2025, and references board and supervisory meetings approving the use of idle raised funds for cash management. There is no indication that this is a full financial report, audit, or earnings release. Instead, it is a regulatory announcement about the company's capital management activities related to raised funds. The document is about financing activities and capital usage updates, specifically the use of idle raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5437 characters) and content support this classification with high confidence.
2025-06-06 Chinese
第五届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 13th meeting of the 5th Supervisory Board of Meikang Biotechnology Co., Ltd. It details the approval of a proposal regarding the use of idle raised funds for cash management. The document includes meeting attendance, voting results, and references to compliance with relevant laws and regulations. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board/management decision related to company fund usage. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1092 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-05-30 Chinese
第五届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 5th Board of Directors of Meikang Biotechnology Co., Ltd. It includes details about the meeting date, attendance, agenda items such as the use of idle raised funds for cash management, and amendments to the company's articles of association (company charter). It also mentions the completion of registration for restricted stock incentive shares and related capital changes. The document is a board meeting resolution announcement rather than a full management report or financial statement. It does not contain financial statements or detailed financial analysis but focuses on board decisions and governance matters. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 1890 characters, which is relatively short and consistent with a board meeting resolution announcement rather than a full report.
2025-05-30 Chinese
《公司章程》修订对照表
Regulatory Filings Classification · 95% confidence The document is a formal announcement from 美康生物科技股份有限公司 regarding amendments to the company's Articles of Association (公司章程). It details changes in registered capital and share capital due to the completion of restricted stock awards. The document references legal compliance and board approval but does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a presentation or voting result announcement. The document is a regulatory announcement about corporate governance changes and capital structure updates, fitting best under Regulatory Filings (RNS) as it does not meet criteria for more specific categories like Share Issue/Capital Change (SHA) because it is primarily about the amendment of the Articles and registration of shares rather than a new share issuance event. The document length is short and it is an announcement rather than a full report.
2025-05-30 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by a listed company for cash management. It includes information about the raised funds, usage status, board and supervisory approvals, risk control measures, and compliance with regulatory requirements. The document is not a full annual or interim financial report, nor is it an earnings release or a call transcript. It is not a simple announcement but a formal verification opinion related to the use of capital raised through a specific issuance. This type of document fits best under the category of Capital/Financing Update (CAP), as it deals with the management and use of raised capital funds and related approvals and oversight.
2025-05-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.